Higher Crohn's disease rates with vedolizumab: a study

Published Date: 13 Mar 2023

The study results may prompt doctors to choose vedolizumab over anti-TNF therapy as the first-line treatment for Crohn's disease.

Read Full News

Latest News

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

AGA Urges Caution Around Surgery for Refractory Constipation in Clinical Practice Update

AGA Urges Caution Around Surgery for Refractory Constipation in Clinical Practice Update

Alcohol-Related Chronic Pancreatitis Linked to Better Outcomes Than Non-Alcohol-Related Disease

Alcohol-Related Chronic Pancreatitis Linked to Better Outcomes Than Non-Alcohol-Related Disease

EBX-102-02 Shows Benefit for IBS-C and IBS-D in Phase 2a TrIuMPH Trial

EBX-102-02 Shows Benefit for IBS-C and IBS-D in Phase 2a TrIuMPH Trial

Q4 2025 Recap: Gastroenterology News and Updates

Q4 2025 Recap: Gastroenterology News and Updates

5 Gastroenterology Headlines You Missed in December 2025

5 Gastroenterology Headlines You Missed in December 2025

Todays Updates

Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus Erythematosus Chelsie Derman

Subcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.

What the EC Decision on High-Dose Spinraza Means for SMA Care Marco Meglio, Stephanie Fradette, PhD

Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.

Dopamine D3 Receptor Mesdopetam Maintains Antidyskinesia Effects Despite Failure to Improve Parkinson Disease ON Time Marco Meglio

A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.

Todays Updates

Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus Erythematosus Chelsie Derman

Subcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.

What the EC Decision on High-Dose Spinraza Means for SMA Care Marco Meglio, Stephanie Fradette, PhD

Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.

Dopamine D3 Receptor Mesdopetam Maintains Antidyskinesia Effects Despite Failure to Improve Parkinson Disease ON Time Marco Meglio

A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.

Latest News

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

AGA Urges Caution Around Surgery for Refractory Constipation in Clinical Practice Update

Alcohol-Related Chronic Pancreatitis Linked to Better Outcomes Than Non-Alcohol-Related Disease

EBX-102-02 Shows Benefit for IBS-C and IBS-D in Phase 2a TrIuMPH Trial

Q4 2025 Recap: Gastroenterology News and Updates

5 Gastroenterology Headlines You Missed in December 2025

News All Time

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Abigail Brooks, MA

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

Small Intestine Dilation Links to Food-Protein-Induced Enterocolitis Syndrome Chelsie Derman

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

The HCPFive: Top News for Healthcare Providers from the Week of 10/05 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

HCPLive 5 Stories in Under 5: Week of 10/05 Victoria Johnson

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

FDA Approves Updated Indication for Upadacitinib (Rinvoq) in IBD Abigail Brooks, MA

The decision updates the indication statements for ulcerative colitis and Crohn’s disease to allow use in patients who have received ≥ 1 approved systemic therapy.

Empirical Donor Selection, 2-Dose Capsule FMT Regimen Improve C Diff Cure Rates Abigail Brooks, MA

Findings from the quality improvement study provide real-world data supporting empirical donor exclusion and multiple-dose capsule FMT to increase CDI cure rates.

ACP Releases Position Paper on Colorectal Cancer Screening, Surveillance Abigail Brooks, MA

The ACP Performance Measurement Committee reviewed 5 performance measures for CRC screening, ultimately only supporting 1 of them.

Conference Preview: American College of Gastroenterology’s 2025 Annual Scientific Meeting Abigail Brooks, MA

View slated expert interviews and 6 clinical GI, hepatology, and endoscopy trials to watch at ACG 2025.

GERD Linked To Heightened Risk of New Alcohol Use Disorder Diagnosis Abigail Brooks, MA

Findings suggest having GERD incurs an 18% greater risk of a new AUD diagnosis, presenting an opportunity to discuss alcohol use with patients.

Emphasizing Bone Health Screening in GI, With Alexandria Markley, MD Alexandria Markley, MD

Markley describes the importance of monitoring bone health in patients with IBD and celiac disease and explains her research showing low screening rates.

Demographic Disparities in GLP-1 RA Trial Enrollment Raise Inclusivity, Validity Concerns Abigail Brooks, MA

Despite bearing a greater obesity burden, Black, Hispanic, and American Indian/Native individuals are underrepresented in GLP-1 RA RCTs for weight loss.

FDA Approves Single-Dose Formulation of Mirikizumab-mrkz for Ulcerative Colitis Ryan Livingston

FDA approves Omvoh (mirikizumab-mrkz) for monthly maintenance of ulcerative colitis, simplifying treatment for patients with this chronic condition.

Solidifying Dupilumab’s Role in Eosinophilic Esophagitis Care, With Evan Dellon, MD, MPH Evan Dellon, MD, MPH

Dellon reviews data from a post-hoc analysis of dysphagia and odynophagia in LIBERTY EoE TREET and a pooled analysis of endoscopic improvement in 2 trials.

Recommended News For You

New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show

Gene therapy and chemotherapy may be combined in novel ways to treat bone cancer.

Immunotherapy after surgery is good for patients with advanced cancer

Big Drop in Cervical Cancer Deaths; Publication Hijackers; A Win for CRC Home Tests

In Patients with Myeloma Who Postpone HSCT, Quadruplet Displays "Excellent Activity.".

FDA Expands Approval of Osimertinib in Lung Cancer

The pandemic had little impact on mental health symptoms.

Recommended Articles For You

Understanding Odontogenic Keratocyst: Symptoms, Causes, and Treatments from Dental Experts 

Uncovering the Mysteries of the RDW Blood Test 

Impact of Hormone Therapy Cessation on Tumor Growth: Case Study of Ki-67 Reduction 

Reshaping the Battlefield Through Tumor Microenvironment Modulation for Cancer Therapy 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.

2.

Discovery of breast cancer treatment resistance mechanism could lead to new hope for some

3.

O. A. J. Simpson passes away from cancer.

4.

Data indicate 1 in 3 US adults unaware of connection between HPV and cancers

5.

Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer

1.

Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study

2.

Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA

3.

Precision Oncology: Tailoring Cancer Treatment for the Individual

4.

AI-Powered Rehabilitation: A Game Changer for Hemophilia Management

5.

Symptoms and Causes of Phlegmasia Cerulea Dolens: A Comprehensive Guide 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Current Scenario of Cancer- Palliative Care to Close the Care Gap

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III

4.

What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?

5.

From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot